Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial



Summary

This phase 2 trial explores a novel approach to overcome resistance to anti-PD-1 immunotherapy in triple-negative breast cancer (TNBC). Researchers aim to activate mast cells, a type of immune cell, to act as antigen-presenting cells (APCs). By boosting the antigen presentation ability of mast cells, the study hopes to enhance the immune response against the tumor. The trial investigates the safety and efficacy of a treatment strategy focused on mobilizing these mast cells in patients with TNBC who have previously failed anti-PD-1 therapy, potentially offering a new therapeutic avenue for this difficult-to-treat cancer.

This post is part of “Immunology News”, Follow for more…!!!

Click on Source link for more details